Oncologic F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography: What All Physicians Need to Know.

Jaime L Montilla-Soler, Rikesh J Makanji, Bruce J Barron

Journal: The American journal of medicine 2019;131(4):357-364

PMID: 29274757

Full Text on Elsevier Science View on PubMed

Abstract

Fluorine-18 fluorodeoxyglucose (F-FDG) positron emission tomography (PET) hybrid examinations (PET/computed tomography, PET/magnetic resonance imaging) have become the most common PET imaging tools in the evaluation of the oncologic patient. Therefore it is of paramount importance that physicians who take care of oncology patients in any capacity are familiar with the basics of when these examinations are indicated, know how to best prepare the patients, and understand the benefits and limitations of the procedure. Additionally, it is important to understand which medical conditions and medications need to be controlled to maintain the diagnostic accuracy of these tests. In this article we aim to explain what F-FDG is, how to best prepare our patients, what PET is, and how these examinations are interpreted. Finally, we discuss some of the limitations of these examinations.

Address: Department of Radiology, H. Lee Moffitt Cancer Center, Tampa, Fla. Electronic address: [email protected].; Department of Radiology, H. Lee Moffitt Cancer Center, Tampa, Fla.; Department of Radiology, Emory University Hospital, Atlanta, Ga.

DOI: 10.1016/j.amjmed.2017.12.006

Link outs

Free resources

Other Literature Sources:

https://scite.ai/reports/29274757

Subscription / membership required

Full Text Sources:

MeSH Terms: Fluorodeoxyglucose F18, Humans, Neoplasms, Positron Emission Tomography Computed Tomography, Radiopharmaceuticals